Aurinia Pharmaceuticals Narrows FY23 Lupkynis (Voclosporin) Sales Guidance Range To $155M-$160M Compared To Prior Range Of $150M-$160M
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals has revised its FY23 sales guidance for Lupkynis (Voclosporin) to a range of $155M-$160M, a slight increase from the previous range of $150M-$160M.
November 02, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals has increased its FY23 sales guidance for Lupkynis, which may indicate increased confidence in the product's performance.
The increase in sales guidance for Lupkynis by Aurinia Pharmaceuticals indicates a positive outlook for the product's performance. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100